COVID-19 Relapse and Viral Evolution in a Good Syndrome Patient: A Case Study

Wataru Sugiura

Center for Clinical Sciences, National Center for Global Health and Medicine

Sign up to read this post
Join Now
Previous
Previous

Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus 3CL protease inhibitor, and relative bioavailability/food effect of a solid formulation…

Next
Next

In vitro antiviral activity of obeldesivir and GS-441524 in combination with oral SARS-CoV-2 therapeutics nirmatrelvir/ritonavir or molnupiravir